vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FULTON FINANCIAL CORP (FULT). Click either name above to swap in a different company.
FULTON FINANCIAL CORP is the larger business by last-quarter revenue ($336.2M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
ESPR vs FULT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $336.2M |
| Net Profit | — | $94.8M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 28.2% |
| Revenue YoY | 143.7% | 4.2% |
| Net Profit YoY | — | 1.9% |
| EPS (diluted) | $0.32 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.2M | ||
| Q4 25 | $168.4M | $336.0M | ||
| Q3 25 | $87.3M | $334.6M | ||
| Q2 25 | $82.4M | $324.1M | ||
| Q1 25 | $65.0M | $318.4M | ||
| Q4 24 | $69.1M | $319.6M | ||
| Q3 24 | $51.6M | $317.7M | ||
| Q2 24 | $73.8M | $334.7M |
| Q1 26 | — | $94.8M | ||
| Q4 25 | — | $99.0M | ||
| Q3 25 | $-31.3M | $100.5M | ||
| Q2 25 | $-12.7M | $99.2M | ||
| Q1 25 | $-40.5M | $93.0M | ||
| Q4 24 | — | $68.6M | ||
| Q3 24 | $-29.5M | $63.2M | ||
| Q2 24 | $-61.9M | $95.0M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 35.7% | ||
| Q3 25 | -11.4% | 38.2% | ||
| Q2 25 | 8.6% | 37.8% | ||
| Q1 25 | -34.0% | 36.1% | ||
| Q4 24 | -6.4% | 27.0% | ||
| Q3 24 | -31.0% | 25.1% | ||
| Q2 24 | 3.5% | 30.8% |
| Q1 26 | — | 28.2% | ||
| Q4 25 | — | 29.5% | ||
| Q3 25 | -35.9% | 30.0% | ||
| Q2 25 | -15.4% | 30.6% | ||
| Q1 25 | -62.2% | 29.2% | ||
| Q4 24 | — | 21.5% | ||
| Q3 24 | -57.2% | 19.9% | ||
| Q2 24 | -83.9% | 28.4% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.32 | $0.53 | ||
| Q3 25 | $-0.16 | $0.53 | ||
| Q2 25 | $-0.06 | $0.53 | ||
| Q1 25 | $-0.21 | $0.49 | ||
| Q4 24 | $-0.14 | $0.36 | ||
| Q3 24 | $-0.15 | $0.33 | ||
| Q2 24 | $-0.33 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $3.5B |
| Total Assets | $465.9M | $32.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $3.5B | ||
| Q4 25 | $-302.0M | $3.5B | ||
| Q3 25 | $-451.4M | $3.4B | ||
| Q2 25 | $-433.5M | $3.3B | ||
| Q1 25 | $-426.2M | $3.3B | ||
| Q4 24 | $-388.7M | $3.2B | ||
| Q3 24 | $-370.2M | $3.2B | ||
| Q2 24 | $-344.2M | $3.1B |
| Q1 26 | — | $32.2B | ||
| Q4 25 | $465.9M | $32.1B | ||
| Q3 25 | $364.0M | $32.0B | ||
| Q2 25 | $347.1M | $32.0B | ||
| Q1 25 | $324.0M | $32.1B | ||
| Q4 24 | $343.8M | $32.1B | ||
| Q3 24 | $314.1M | $32.2B | ||
| Q2 24 | $352.3M | $31.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $304.5M | ||
| Q3 25 | $-4.3M | $116.1M | ||
| Q2 25 | $-31.4M | $91.7M | ||
| Q1 25 | $-22.6M | $703.0K | ||
| Q4 24 | $-35.0M | $416.6M | ||
| Q3 24 | $-35.3M | $-22.0M | ||
| Q2 24 | $-7.2M | $157.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.08× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 6.07× | ||
| Q3 24 | — | -0.35× | ||
| Q2 24 | — | 1.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FULT
Segment breakdown not available.
